Home PageHome Page
Video news on demand for all screens
  
 EN

FDA BIRTH CONTROL WARNING LABELS

FILE

ID # 132 346 5304
post 1323465304
NATIONAL

Licensing conditions


This content can be licensed for the following media usages:
Mobile TV
National TV - News
National TV - Shows
Web TV


Within the following territories or with the following restrictions & embargoes in these territories:
NO United States (USA)

and its territories.

Licensing online is available within 60 days after release date. Extra clearing is necessary after 60 days.

WARNING #1: Sports fields' & games' extracts CANNOT be used without the explicit agreement of the sports leagues!

WARNING #2: some extra embargoes and restrictions may apply as detailed in the attached dopesheet visible when logged-in >>> >>>

Complementary information

Recorded: Fri 09 Dec 2011, 15:07 GMT
Released: Fri 09 Dec 2011, 20:46 GMT

Subject(s):
- health

Location: United States (USA), UNITED STATES (USA)

United States (USA), UNITED STATES (USA), Fri 09 Dec 2011, 15:07 GMT

U.S. HEALTH ADVISERS RECOMMEND REVISING THE WARNING LABELS ON NEWER FORMS OF ORAL CONTRACEPTIVES.

A FOOD AND DRUG ADMINISTRATION ADVISORY PANEL VOTED IN FAVOR OF NEW LABELS FOR CONTRACEPTIVES CONTAINING DROSPIRENONE (dro-spir-a-none).
THE MAN-MADE PROGESTIN MAY INCREASE CHANCES OF DANGEROUS CLOTS IN THE LEGS AND LUNGS ... COMPARED TO OLDER FORMS OF BIRTH CONTROL PILLS.
SEVERAL DOCTORS SAID IN ADVANCE OF THE HEARING THE POTENTIAL INCREASED RISK OF CLOTS IS NOT GREAT... BUT THEY ADDED IT SHOULD NOT BE DISMISSED EITHER.
IN A STATEMENT BAYER SAYS THEY'VE CONSISTENTLY WORKED WITH REGULATORY AUTHORITIES AROUND THE WORLD AS NEW DATA ON DROSPIRENONE HAS BECOME AVAILABLE... AND THEY WILL CONTINUE TO DO SO.
THE PANEL'S RECOMMENDATION STILL NEEDS F-D-A APPROVAL.
USUALLY THE F-D-A FOLLOWS THE PANEL'S ADVICE.







Terms & Conditions of use - FAQ - Publisher's legal mention - About Akamedia
All Contents, media assets and previews belong to the producers. Everything else is © 2005-2012 Newspusher & Akamedia. All rights reserved.